Not yet recruiting
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
NCT03356782
- Conditions
- Bone Diseases, Bone Neoplasms, Diabetes Mellitus, Insulin-Dependent, 12, +12 more
- Locations
-
- Shenzhen Geno-immune Medical Institute Shenzhen, Guangdong, China